Equity
€2.3m ▲ 6.6%
ROMAPHARM has made a profit without a break since 2009.
ROMAPHARM
Lifetime
20 annual accounts with figures on one time axis, 30 filings since 1996peak €826,320 (2021)
€605,275▼ 10.4%
lowest -€40,251 (2008)
€140,883▼ 27.4%
peak €2.3m (2025)
€2.3m▲ 6.6%
€682,312▼ 6.5%
peak 9 FTE (2016)
5.6 FTE▲ 5.7%
Board4 names since 2018
3 directors and 2 others
Documentsfilings and deeds
10-06-202651 days before the deadline
2025abbreviated format
Result from €194,092 to €140,8831 director appointed, 1 resignation, 1 reappointment 06-08Cash from €140,972 to €344,630
Key points
from the 2025 annual accountsResult
€140,883 ▼ 27.4%
The result fell in 2025 from €194,092 to €140,883.
Turnover
≈ €2.2m estimated
The abbreviated format states no turnover.
Staff
5.6 FTE from 9 in 2016
Between 2016 and 2025, 38% of the full-time equivalents disappeared.
Filings
30 annual accounts since 1996
The last five annual accounts were filed 31 to 103 days before the end of the period.
Position in the sector
€2.3m
More equity than 95% of companies in retail trade. Sector median €315,153 · 13,237 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 17,035 companies had the same profile as ROMAPHARM has now. Each dot stands for 43 companies, two years later.
94.4%
were still trading
4.9%
stopped another way
0.5%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 17,035 companies, not a prediction for ROMAPHARM. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0456909689
1 director appointed, 1 resignation, 1 reappointment
Resignation: (managing director) · Appointment: (managing director) · Permanent representatives: and · General meeting of 21-03-2025 · Gazette deed
3 directors resigning, 3 reappointments
Resignations: , and · Reappointments: , and · Permanent representative: · General meeting of 04-05-2022 · Gazette deed
3 directors reappointed
, and · Permanent representative: · General meeting of 29-06-2018 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ROMAPHARM Koksijde | €3.0m | €605,275 | 77.0% | 5.6 |
| LINAPO Lubbeek | €3.0m | €652,971 | 77.8% | 6.5 |
| Pharmacie Savenay Neupré | €3.5m | €515,029 | 21.5% | 6.4 |
| APOTHEEK DEBRUYNE - DESRUMAUX Bruges | €2.9m | €606,045 | 38.9% | 4.5 |
| APOTHEEK DE LOORE WINGENE Wingene | €2.6m | €534,472 | 19.8% | 6.9 |
| APOTHEEK MAHIEU Waregem | €2.3m | €622,727 | 73.9% | 4.1 |
| Apotheek Meense & Delta Roeselare | €3.3m | €916,383 | 69.3% | 4.7 |
These companies have the same main activity as ROMAPHARM: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €2.3m and €3.5m, founded between 1988 and 2003.
Official details
Source: KBO- Status
- Active since 22-12-1995Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730and 1 other
- Joint committees
- 201Independent retail
- 313Pharmacies and pricing offices · annual accounts 2025
- Establishment units
- 2.074.897.3068670 Koksijde, since 12-02-1996
- 2.074.897.4058670 Koksijde, since 12-02-1996and 1 other
- Financial year end
- 31 December
- Peppol
- Reachable since 24-09-2025
Annual accounts 2025
- €3.0m▲ 3.2%
- Employeeson 31-12-2025
- 7▲ 16.7%
- Filing
- Filed on 10-06-2026, 51 days before the end of the filing period
Insights on ROMAPHARM
ROMAPHARM files the abbreviated format. That format states no turnover. The gross margin rose from €516,346 in 2006 to €605,275 in 2025.
The balance sheet grew most from 2008 to 2010 through fixed assets.
In August 2025, the Official Gazette published the appointment of . as managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ROMAPHARM
- What is the company number of ROMAPHARM?
- The company number of ROMAPHARM is 0456.909.689. The VAT number is the same number with BE in front: BE 0456.909.689.
- Where is ROMAPHARM based?
- The registered office is at Koninklijke Baan 102, 8670 Koksijde.Company details
- What does ROMAPHARM do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of ROMAPHARM?
- ROMAPHARM is a public limited company (NV).
- When was ROMAPHARM founded?
- ROMAPHARM was founded on 22-12-1995.
- Is ROMAPHARM still active?
- Yes, ROMAPHARM is an active enterprise in the KBO register.
- How many employees does ROMAPHARM have?
- ROMAPHARM had an average of 5.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does ROMAPHARM fall under?
- In its 2025 annual accounts, ROMAPHARM states joint committees 201 (Independent retail) and 313 (Pharmacies and pricing offices).
- What is the turnover of ROMAPHARM?
- The turnover in financial year 2025 is ≈ €2.2m. This figure is estimated from the gross margin of €605,275 and 47 comparable companies (NACE 477). It probably lies between €1.6m and €3.4m.
- Is ROMAPHARM profitable?
- In financial year 2025, ROMAPHARM made a profit of €140,883.
- Where can I find the annual accounts of ROMAPHARM?
- ROMAPHARM filed 30 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ROMAPHARM due?
- ROMAPHARM must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.